Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The clinical utility of docetaxel in adriamycin resistant breast cancer

  • 25 Accesses


Taxanes were developed as third-generation anticancer agents following methotrexate and adriamycin, two major chemotherapeutic agents for breast cancer. These agents have been studied to confirm antitumor effects in anthracycline-resistant patients and patients with liver metastasis. In this study, we examined the usefulness of taxanes, especially docetaxel, in chemotherapy for breast cancer by reviewing results in Japan and other countries. In a late phase II clinical study in Japan, the administration of 60 mg/m2/hr/3-4w of docetaxel (DOC) reduced tumor size in 50.4% of patients. In 6% of these patients, complete response (CR) was achieved. The duration of response was 14.7 weeks. Thirty-five percent of 26 primary adriamycin (ADM)-resistant patients responded to DOC treatment (CR: 4.0%).

This is a preview of subscription content, log in to check access.













  1. 1)

    Rowinsky EK, Donehower RC: Paclitaxel (Taxol).N Engl J Med 332:1004–1014, 1995.

  2. 2)

    Oosterom AT, Schriivers D: Docetaxel (Taxotere), a review of preclinical and clinical experience, Part II; clinical experience.Anti-Cancer Drugs 6:356–368, 1995.

  3. 3)

    Ringel I, Horwitz SB: Studies with RP56976 (Taxotere); A semisynthetic analog of taxol.J Natl Cancer Inst 83:288–291, 1991.

  4. 4)

    Lavelle F, Bissery MC, Combeau Cet al: Preclinical evaluation of docetaxel (Taxotere).Semin Oncol 22:3–16 1995.

  5. 5)

    Taguchi T, Furne H, Niitani H,et al: Phase I clinical trial of RP56976 (Docetaxel); A new anticancer drug.Jpn J Cancer Chemother 21:1997–2005, 1994.

  6. 6)

    Chevallier B Funmoleau P, Kerbrat P,et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer; A phase II trial of the clinical Screening cooperative group of the European organization for research and treatment of cancer.J Clin Oncol 13:314–322, 1995.

  7. 7)

    Dieras V, Chevallier B Kerbrat P,et al: A multicentre phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer; Report of the Clinical Screening Group of the EORTC.Br J Cancer 74:650–656, 1996.

  8. 8)

    Trudeau ME, Eisenhauer E, Lofters W,et al: Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC); A National Cancer Institute of Canada Clinical Trial Group (NCICCTG) study.Proc Am Soc Clin Oncol 12:63, 1993 (abstr 59).

  9. 9)

    Hudis CA, Seidman AD, Crown JPA,et al: Phase II and pharmologic study of docetaxel as initial chemotherapy for metastatic breast cancer.J Clin Oncol 14: 58–65, 1996.

  10. 10)

    Huinink WWB, Prove AM, Picart M,et al: A phase II trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer; A study of the EORTC early clinical trials group.Ann Oncol 5:527–532, 1994.

  11. 11)

    Valero V, Burris III HA, Jones’s,et al: Multicenter pilot study of taxotere in taxol-resistant metastatic breast cancer (MBC).Proc Am Soc Clin Oncol 15:107, 1996 (abstr 95).

  12. 12)

    Taguchi T, Mori S, Abe R,et al: Late phase II clinical study of RP 56976 (Docetaxel) in patients with advanced/recurrent breast cancer.Jpn J Cancer Chemother 21:2625–2632, 1994.

  13. 13)

    Adachi I, Watanabe T, Takashima S,et al: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.Br J Cancer 73:210–216, 1996.

  14. 14)

    Ravdin PM, Burris III HA, Cook G,et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.J Clin Oncol 13:2879–2885, 1995.

  15. 15)

    Valero V, Holmes FA, Walters RS,et al: Phase II trial of docetaxel; A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.J Clin Oncol 13:2886–2894, 1995.

  16. 16)

    Chan S, Friedrichs K, Noël D,et al: A randomized phase III study of taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen; Preliminary results.Proc Am Soc Clin Oncol 16:154a, 1997 (abstr 540).

  17. 17)

    Paridaens R, Bruning P, Klijn J,et al: An EORTC crossover trial comparing single-agent taxol (T) and doxorubicin (D) as first- and second-line chemotherapy (CT) in advanced breast cancer (ABC).Proc Am Soc Clin Oncol 16:154a, 1997 (abstr 539).

  18. 18)

    Norris B, Pritchard K, James K,et al: A Phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/recurrent breast cancer (MBC); A National Cancer Institute of Canada (NCICCTG) study.Proc Am Soc Clin Oncol 15:98, 1996 (abstr 59).

  19. 19)

    Perez DJ, Harvey VJ, Robinson BA,et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.J Clin Oncol 9:2148–2152, 1991.

  20. 20)

    Henderson IC, Allegra JC, Woodcock T,et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.J Clin Oncol 7:560–571, 1989.

  21. 21)

    Taguchi T, Ogawa M, Izuo M,et al: A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer.Jpn J Cancer Chemother 13:3498–3507, 1986.

  22. 22)

    Dieras V, Bourgeois H, Guria G,et al: Docetaxel (D) in combination with doxorubicin (Dx) as 1st line CT of metastatic breast cancer (MBC); A phase I dose finding study.Proc Am Soc Clin Oncol 15:148, 1996 (abstr 259).

  23. 23)

    Kennedy MJ, Elza K, Donehower R,et al: Phase I and pharmacologic (PK) study of docetaxel and doxorubicin in patients (pts) with solid tumors; Dose limiting toxicity at first dose levels.Proc Am Soc Clin Oncol 16:240a, 1997 (abstr 845).

  24. 24)

    Valeriola D de, Brassine Kerger J,et al: Clinical and phamacokinetic phase I study of docetaxel (TXT) combined to continuous infusion (CI) of 5-fluorouracil (FU) in advanced breast cancer patients.Proc Am Soc Clin Oncol 16:221a, 1997 (abstr 774).

  25. 25)

    Sano M, Adachi I, Watanabe T,et al: A phase I /II study of docetaxel (TXT) in combination with infusion of fluorouracil (5-FU) in patients with advanced or recurrent breast cancer.Proc Am Soc Clin Oncol 16:189a, 1997 (abstr 665).

  26. 26)

    Crown J, Fumoleau P, Kerbrat P,et al: Phase I trial of docetaxel (D) with cisplatin (P) as first-line chemotherapy of metastatic breast cancer (MBC).Proc Am Soc Clin Oncol 16:233a, 1997 (abstr 821).

  27. 27)

    Valero V, Esparza-Guerra L, Rahman Z,et al: Phase I study of docetaxel (taxotere) and cyclophsphamide without and with G-CSF in previously treated and untreated solid tumors.Proc Am Soc Clin Oncol 16:220a, 1997 (abstr 772).

  28. 28)

    Fumoleau P, Delecroix V, Perrocheau G,at al: Final results of a phase I dose finding and pharmacokinetic (P.study of docetaxel in combination with vinorelbine in metastatic breast cancer.Ann Oncology 7(Suppl 5): 126, 1996.

  29. 29)

    Nabholtz JM, Mackey JR, Smylie M,et al: Phase II study of taxotere (docetaxel), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC).Proc Am Soc Clin Oncol 16:148a, 1997 (abstr 518).

  30. 30)

    Antoine EC, Coeffic D, Gozy M,et al: A Phase II study of docetaxel (T) and cisplatin (P) in anthracycline (A)-pretreated metastatic breast cancer (PMBC); Preliminary results.Proc Am Soc Clin Oncol 16:158a, 1997 (abstr 551).

  31. 31)

    Colman AJ, Goldie JH: Factors affecting the development of permanent drug resistance and impact upon neoadjuvant chemotherapy.Recent Results Cancer Res 103:69–78, 1986.

  32. 32)

    Sledge Jr GW, Robert N, Sparano JA,et al: Eastern cooperative oncology group studies of paclitaxel and doxorubicin in advanced breast cancer.Semin Oncol 22:105–108, 1995.

  33. 33)

    Piccart-Gebhart MJ, Bruning P, Gamucci T,et al: An ongoing European organization for research and treatment of cancer crossover trial comparing singleagent paclitaxel and doxorubicin as first-and second-line treatment of advanced breast cancer.Semin Oncol 23:11–15, 1996.

Download references

Author information

Correspondence to Isamu Adachi or Tetsuo Taguchi.

About this article

Cite this article

Adachi, I., Taguchi, T. The clinical utility of docetaxel in adriamycin resistant breast cancer. Breast Cancer 4, 273–279 (1997). https://doi.org/10.1007/BF02966521

Download citation

Key words

  • Docetaxel
  • Chemotherapy
  • Metastatic breast cancer
  • Adriamycin-resistant
  • Liver metastasis